Magdalena G Dorywalska

US Patent:

20130230543, Sep 5, 2013

Filed:

Nov 3, 2011

Appl. No.:

13/883535

Inventors:

Jaume Pons - South San Francisco CA, US
Arvind Rajpal - South San Francisco CA, US
Pavel Strop - South San Francisco CA, US
Magdalena Grazyna Dorywalska - South San Francisco CA, US
David Shelton - South San Francisco CA, US
Shu-Hui Liu - South San Francisco CA, US
Russell Dushin - Groton CT, US

International Classification:

C07K 17/02

US Classification:

4241781, 5303913, 435 681

Abstract:

The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.

US Patent:

20130122020, May 16, 2013

Filed:

Nov 7, 2012

Appl. No.:

13/670730

Inventors:

Pavel STROP - San Mateo CA, US
Magdalena Grazyna DORYWALSKA - Redwood City CA, US
Arvind RAJPAL - San Francisco CA, US
David Louis SHELTON - Oakland CA, US

Assignee:

RINAT NEUROSCIENCE CORP. - San Diego CA

International Classification:

C07K 16/30

US Classification:

4241741, 5303897, 5303873, 5303917, 5303919, 4241781, 536 2353, 4353201, 4353441, 43525233, 43525231, 43525421, 4352542, 435 696

Abstract:

The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.

US Patent:

20210205463, Jul 8, 2021

Filed:

Feb 23, 2021

Appl. No.:

17/183265

Inventors:

- New York NY, US
Magdalena Grazyna DORYWALSKA - Redwood City CA, US
Ludivine MOINE - Uncasville CT, US

Assignee:

PFIZER INC. - New York NY
RINAT NEUROSCIENCE CORP. - New York NY

International Classification:

A61K 47/65
A61K 47/64
A61K 47/68

Abstract:

The present invention provides stability-modulated antibody-drug conjugates, stability-modulating linker components used to make these stability-modulated antibody-drug conjugates, therapeutic methods using stability-modulated antibody-drug conjugates, and methods of making stability modulating linkers and stability-modulated antibody-drug conjugates.

US Patent:

20190002559, Jan 3, 2019

Filed:

Sep 7, 2018

Appl. No.:

16/125032

Inventors:

- SOUTH SAN FRANCISCO CA, US
Pavel Strop - San Mateo CA, US
Magdalena Grazyna Dorywalska - Redwood City CA, US
Arvind Rajpal - San Francisco CA, US
David Louis Shelton - Oakland CA, US

Assignee:

RINAT NEUROSCIENCE CORP. - SOUTH SAN FRANCISCO CA

International Classification:

C07K 16/28
C07K 16/30
A61K 47/68
A61K 38/08

Abstract:

The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.

US Patent:

20180140714, May 24, 2018

Filed:

Aug 14, 2015

Appl. No.:

15/504801

Inventors:

- New York NY, US
- South San Francisco CA, US
Magdalena Grazyna DORYWALSKA - Redwood City CA, US
Ludivine MOINE - Uncasville CT, US

Assignee:

PFIZER INC. - New York NY
RINAT NEUROSCIENCE CORP. - South San Francisco CA

International Classification:

A61K 47/65
A61K 47/68
A61K 47/64

Abstract:

The present invention provides stability-modulated antibody-drug conjugates, stability-modulating linker components used to make these stability-modulated antibody-drug conjugates, therapeutic methods using stability-modulated antibody-drug conjugates, and methods of making stability modulating linkers and stability-modulated antibody-drug conjugates.

US Patent:

20170043033, Feb 16, 2017

Filed:

Apr 21, 2015

Appl. No.:

15/306481

Inventors:

- South San Francisco CA, US
- New York NY, US
Magdalena DORYWALSKA - Redwood City CA, US
Davide Luciano FOLETTI - Menlo Park CA, US
Russell George DUSHIN - Old Lyme CT, US
David Louis SHELTON - Oakland CA, US
Arvind RAJPAL - San Francisco CA, US

Assignee:

RINAT NEUROSCIENCE CORP. - South San Francisco CA
PFIZER INC. - NEW YORK NY

International Classification:

A61K 47/48
G01N 33/574
C07K 16/30
A61K 31/427

Abstract:

The present invention provides transglutaminase-mediated antibody-drug conjugates with high anti-body-drug ratio (DAR) comprising 1) glutamine-containing tags, endogenous glutamines, and/or endogenous glutamines made reactive by antibody engineering or an engineered transglutaminase (e.g., with altered substrate specifity); and 2) amine donor agents comprising amine donor units, linkers, and agent moieties, wherein the DAR is at least about 5. The invention also provides methods of making and methods of using such higher drug loaded antibody-drug conjugates.

US Patent:

20160257746, Sep 8, 2016

Filed:

May 20, 2016

Appl. No.:

15/160742

Inventors:

- SOUTH SAN FRANCISCO CA, US
Pavel STROP - San Mateo CA, US
Magdalena Grazyna DORYWALSKA - Redwood City CA, US
Arvind RAJPAL - San Francisco CA, US
David Louis SHELTON - Oakland CA, US

International Classification:

C07K 16/28
C07K 16/30
A61K 47/48

Abstract:

The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.

US Patent:

20140357844, Dec 4, 2014

Filed:

Aug 15, 2014

Appl. No.:

14/460871

Inventors:

- South San Francisco CA, US
Pavel STROP - San Mateo CA, US
Magdalena Grazyna DORYWALSKA - Redwood City CA, US
Arvind RAJPAL - San Francisco CA, US
David Louis SHELTON - Oakland CA, US

International Classification:

A61K 47/48
A61K 38/08
C07K 16/28

US Classification:

5303919, 536 2353, 4353201, 435331, 43525233, 43525231, 4352542, 43525421

Abstract:

The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.